BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:VM Discovery\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies VM Discovery\, Inc.'s drugs run\,
  from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07636785-2798@assetmemo.bio
DTSTAMP:20261121T005448Z
DTSTART;VALUE=DATE:20310531
DTEND;VALUE=DATE:20310601
SUMMARY:VMD-102: Phase 1/2 readout est. (NCT07636785)
DESCRIPTION:VMD-102\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Pha
 se 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tu
 mors\nEstimated primary completion: May 2031. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/vmd-102#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07636785
URL:https://assetmemo.bio/drug/vmd-102#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
